Turkish Journal of Medical Sciences
Abstract
Background/aim: Our purpose was to determine the efficacy of levodopa carbidopa intestinal gel (LCIG) in a series of Turkish patients with Parkinson's disease (PD). Materials and methods: We had telephone calls with 54 patients from 11 neurology centers who were on LCIG treatment, and 44 patients or their caregivers were included in an eight-item survey between September 2015 and June 2016. The reliability and validity of the survey were evaluated with intraclass correlation coefficients for every question separately.Results: Average age of the patients were 63.48 and the duration of PD was 12.79 years. Average LCIG treatment period was 15.63 months. Percentages of the patients who reported they were `better' after LCIG treatment were as follows: 80% for time spent off, 55% for dyskinesia, 65% for tremor, 85% for gait disorder, 50% for pain, 50% for sleep disorders, 42.5% for depression, 32.5% for incontinence, and 70% for activities of daily living. Cronbach's alpha was 0.795 and the intraclass correlation coefficient was reliable for the items.Conclusion: As detected by a survey performed by telephone calls with good interrater reliability, patients with PD improve with LCIG treatment in many aspects of the disease.
DOI
10.3906/sag-1904-150
Keywords
Parkinson's disease, levodopa carbidopa intestinal gel, efficacy
First Page
66
Last Page
85
Recommended Citation
GÜLTEKİN, MURAT; ULUKAN, ÇAĞRI; AYDEMİR, SABİHA TEZCAN; DOĞU, OKAN; HANAĞASI, HAŞMET AYHAN; BİLGİÇ, BAŞAR; TOKÇAER, AYŞE BORA; ÇAKMUR, RAİF; ELİBOL, BÜLENT; MİRZA, MERAL; GÜNAL, DİLEK; ÖZBEK, ÇİĞDEM SEVDA ERER; KENANGİL, GÜLAY; KÜSBECİ, ÖZGE YILMAZ; and AKBOSTANCI, MUHİTTİN CENK
(2020)
"Multicenter study of levodopa carbidopa intestinal gel in Parkinson's disease: the Turkish experience,"
Turkish Journal of Medical Sciences: Vol. 50:
No.
1, Article 11.
https://doi.org/10.3906/sag-1904-150
Available at:
https://journals.tubitak.gov.tr/medical/vol50/iss1/11
